Diabetes Treatment Report

www.DiabetesTreatmentReport.com

Phase 1

A Study to Look at How Safe NNC0268-0965 (insulin 965) is in Healthy People and People With Type 1 Diabetes

https://clinicaltrials.gov/ct2/show/NCT03965013?type=Intr&cond=type+1+diabetes&phase=012345&sfpd_d=14&lupd_s=02%2F10%2F2019&lupd_e=05%2F29%2F2019&sort=nwst&sel_rss=new14

STUDY TITLE:
A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

DESCRIPTION:
Conditions:   Diabetes Mellitus, Type 1;   Healthy Volunteers
Interventions:   Drug: NNC0268-0965;   Drug: Placebo;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Not yet recruiting

CLINICALTRIALS.GOV IDENTIFIER:
NCT03965013

FIRST POSTED:
Mon, 27 May 2019 12:00:00 EDT

LAST UPDATE POSTED:
05/29/19 02:17PM

STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03965013?type=Intr&cond=type+1+diabetes&phase=012345&sfpd_d=14&lupd_s=02%2F10%2F2019&lupd_e=05%2F29%2F2019&sort=nwst&sel_rss=new14

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

https://clinicaltrials.gov/ct2/show/NCT03895996

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

Study Type : Interventional
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1 / 2 Double-Blind, Randomized, Placebo Controlled Study of Safety, Tolerability and Potential Efficacy of AVOTRES Cell-Based Therapy (AVT001) in Patients With Type 1 Diabetes
Estimated Study Start Date : June 2019
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : June 2022

Polyclonal Regulatory T Cell (PolyTreg) Immunotherapy in Islet Transplantation

https://clinicaltrials.gov/ct2/show/NCT03444064

PolyTreg Immunotherapy in Islet Transplantation

Study Type : Interventional
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Polyclonal Regulatory T Cell (PolyTreg) Immunotherapy in Islet Transplantation
Actual Study Start Date : February 1, 2018
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2021

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes

https://clinicaltrials.gov/ct2/show/NCT03624062

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes (MER3101)

Study Type : Interventional
Estimated Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes
Estimated Study Start Date : January 2019
Estimated Primary Completion Date : April 4, 2022
Estimated Study Completion Date : April 4, 2022

Study Evaluating the Safety of Islet Transplant in Patients With Type I Diabetes

https://clinicaltrials.gov/ct2/show/NCT03698396

Islet Transplant in Patients With Type I Diabetes

Study Type : Interventional
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Open-Arm Study Evaluating the Safety of Islet Transplant in Patients With Type I Diabetes
Estimated Study Start Date : November 1, 2018
Estimated Primary Completion Date : November 1, 2021
Estimated Study Completion Date : December 1, 2023

Back to top